Wanbury Limited Posts Strong FY26 Results with 117% Profit Growth and Doubled Earnings Per Share
Wanbury Limited, a pharmaceutical manufacturer with a significant global active pharmaceutical ingredient (API) presence and a portfolio of domestic branded formulations, unveiled its audited financial results for the fourth quarter and full year FY26.
Full Year Results
The company demonstrated robust profitability expansion across key metrics. Net profit for FY26 reached ₹66.1 crore, representing a 116.6% increase from ₹30.5 crore in FY25. Earnings per share more than doubled, climbing to ₹20.55 from ₹9.32 in the previous year, a 122% jump.
Revenue from operations grew 8.5% year-on-year to ₹650.3 crore compared to ₹599.5 crore in FY25. EBITDA (including other income) expanded substantially by 34.9% to ₹107.7 crore from ₹79.8 crore, while EBITDA margins widened by 330 basis points to 16.5%.
Profit margins improved significantly, with net profit margin expanding by 509 basis points to reach 10.2% in FY26.
Fourth Quarter Performance
In the final quarter, revenue stood at ₹164.6 crore against ₹172.0 crore in Q4 FY25, a decline of 4.3% year-on-year. The company attributed this contraction to disruptions in API exports caused by the West Asia crisis in late February.
Despite the revenue headwind, quarterly net profit reached ₹21.7 crore, up 7.2% from ₹20.2 crore in the corresponding quarter last year. The quarter included a one-time charge of ₹3.6 crore related to new labour codes. Quarterly net profit margin improved by 150 basis points to 13.2%. EBITDA for the quarter stood at ₹30.1 crore, while gross margin expanded significantly by 887 basis points year-on-year to 60.4%.
Operational and Business Developments
The company commissioned a new Anaesthetic API facility at its Tanuku location following completion of capital expenditure, with commercial shipments to Europe commencing in February 2026. The company's API pipeline has been strengthened with upcoming launches of Dextromethorphan HBr, Rivaroxaban, and Sitagliptin.
Regulatory achievements strengthened the company's market position. The Medicines and Food Safety Bureau, Korea conducted an inspection from 7-9 April 2026, which concluded with zero observations. Previously, the company received zero observations during a USFDA inspection at its Patalganga facility and zero observations in an ANVISA Brazil inspection. ANVISA approval was secured for Sertraline Form II, enhancing access to regulated markets in Brazil.
The company continued investing in process optimization, debottlenecking, and manufacturing upgrades to enhance capacity and operational leverage. The implementation of SAP HANA S4 enterprise resource planning software contributed to operational efficiencies across the organization. The formulations business showed improvement with new product launches across paediatric, nutraceutical, and specialty segments.
Management Perspective
Mohan Rayana, Director at Wanbury Limited, stated: "FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisation, enhanced product yields, and procurement efficiencies supported better EBITDA margins.
"The fourth quarter saw a revenue decline due to the West Asia crisis impacting API exports. Despite this, we continued growth on the back of new product launches in Q4. A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. Clearing MFDS Korea inspection with zero observations validates our compliance systems. We will continue our API growth journey in FY27 with recent launches and a strong pipeline, while the formulations business will operate from a stronger footing supported by new launches and improved go-to-market strategy."
Compare options


